Marily Theodoropoulou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marily Theodoropoulou has a total of 309 co-authors. Here are the top co-authors by number of shared publications:
- Martin Reincke
Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany
10 shared publications Jörg Flitsch
Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
8 shared publicationsMichael Buchfelder
Department of Neurosurgery, University of Erlangen-Nürnberg, Erlangen, Germany
6 shared publicationsJürgen Honegger
Department of Neurosurgery, University of Tübingen, Tübingen, Germany
5 shared publications- Luis Gustavo Perez-Rivas
Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU Medizin Ludwig‐Maximilians‐Universität München Munich Germany
5 shared publications Martin Reincke
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany
5 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (10)
Cushing's syndrome is associated with an advanced chronotype
Cushing's syndrome is characterised by chronic glucocorticoid excess that abolishes the physiological circadian cortisol rhythm. We investigated whether this circadian disruption alters chronotype. In a single‐centre case–control study, chronotype was assessed using the Munich ChronoType Questionnaire (MCTQ; n = 119) and wrist actigraphy ( n = 39) in patients with active Cushing's syndrome, patients in biochemical remission, and healthy controls. The primary outcome was mid‐sleep on free days corrected for sleep debt (MSFsc). Multivariable analysis was performed to identify independent predictors of chronotype. Agreement between methods was assessed by Bland–Altman analysis. Patients with active Cushing's syndrome had a significantly earlier chronotype than patients in remission and controls (MSFsc by MCTQ: 2.38 h [IQR 1.22; 3.41] vs. 3.29 h [IQR 2.65; 4.32] vs. 3.73 h [IQR 3.16; 4.08]; p = .007 and p = .0003, respectively; actigraphy: 3.15 ± 0.90 h vs. 4.03 ± 0.96 h vs. 4.46 ± 0.75 h; p = .039 and p = .001, respectively). Chronotype did not differ significantly between patients in remission and controls. In a multivariable quantile regression model, active Cushing's syndrome was an independent predictor of chronotype (1.32 h earlier than controls; p = .049), while age, BMI, psychiatric symptoms and sleep disturbance had no significant influence. Actigraphy confirmed earlier sleep offset and acrophase in active Cushing's syndrome. MCTQ and actigraphy were significantly correlated (Pearson r = 0.619, p = .0003, n = 29); agreement analysis revealed no systematic bias, but a significant proportional bias, reflecting wider dispersion of MCTQ‐derived values. Patients with active Cushing's syndrome have an earlier chronotype than patients in remission and healthy controls, as determined by both subjective and objective methods. Chronotype assessment, particularly with the MCTQ, may complement biochemical monitoring.
- 8 October 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (10)
Open AccessCushing's syndrome is associated with an advanced chronotype
Cushing's syndrome is characterised by chronic glucocorticoid excess that abolishes the physiological circadian cortisol rhythm. We investigated whether this circadian disruption alters chronotype. In a single‐centre case–control study, chronotype was assessed using the Munich ChronoType Questionnaire (MCTQ; n = 119) and wrist actigraphy ( n = 39) in patients with active Cushing's syndrome, patients in biochemical remission, and healthy controls. The primary outcome was mid‐sleep on free days corrected for sleep debt (MSFsc). Multivariable analysis was performed to identify independent predictors of chronotype. Agreement between methods was assessed by Bland–Altman analysis. Patients with active Cushing's syndrome had a significantly earlier chronotype than patients in remission and controls (MSFsc by MCTQ: 2.38 h [IQR 1.22; 3.41] vs. 3.29 h [IQR 2.65; 4.32] vs. 3.73 h [IQR 3.16; 4.08]; p = .007 and p = .0003, respectively; actigraphy: 3.15 ± 0.90 h vs. 4.03 ± 0.96 h vs. 4.46 ± 0.75 h; p = .039 and p = .001, respectively). Chronotype did not differ significantly between patients in remission and controls. In a multivariable quantile regression model, active Cushing's syndrome was an independent predictor of chronotype (1.32 h earlier than controls; p = .049), while age, BMI, psychiatric symptoms and sleep disturbance had no significant influence. Actigraphy confirmed earlier sleep offset and acrophase in active Cushing's syndrome. MCTQ and actigraphy were significantly correlated (Pearson r = 0.619, p = .0003, n = 29); agreement analysis revealed no systematic bias, but a significant proportional bias, reflecting wider dispersion of MCTQ‐derived values. Patients with active Cushing's syndrome have an earlier chronotype than patients in remission and healthy controls, as determined by both subjective and objective methods. Chronotype assessment, particularly with the MCTQ, may complement biochemical monitoring.
- Open Access
- 4 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7777
Multi-omics integration unravels four molecular subgroups of corticotroph pituitary neuroendocrine tumours with distinct clinicopathological features
Corticotroph pituitary neuroendocrine tumours (PitNETs)/adenomas are heterogeneous sellar neoplasms. Currently established histopathological classification approaches are often considered limited in fully capturing the clinical and biological complexity of these tumours. Thus far, a molecular-based classification has not been established in corticotroph PitNETs. We compile molecular data of 270 corticotroph PitNETs (111 internal, 159 external), encompassing epigenome, transcriptome, and proteome profiles. Comprehensive integrative analyses are performed to identify, validate and characterise definitive molecular subgroups. Corticotroph PitNETs separate into four robust and clinicopathologically distinct molecular subgroups, which are broadly distinguishable by microscopy using SSTR1, GATA3 and SSTR5 immunohistochemistry. An integrated stratification model incorporating these molecular subgroups demonstrates significant prognostic utility. Our findings support the establishment of a refined molecular-based corticotroph PitNET classification, the full clinical value of which will require validation in prospective studies. To facilitate future research, we provide an easy-to-use epigenomic classifier for corticotroph PitNETs.
- 4 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7777
Open AccessMulti-omics integration unravels four molecular subgroups of corticotroph pituitary neuroendocrine tumours with distinct clinicopathological features
Corticotroph pituitary neuroendocrine tumours (PitNETs)/adenomas are heterogeneous sellar neoplasms. Currently established histopathological classification approaches are often considered limited in fully capturing the clinical and biological complexity of these tumours. Thus far, a molecular-based classification has not been established in corticotroph PitNETs. We compile molecular data of 270 corticotroph PitNETs (111 internal, 159 external), encompassing epigenome, transcriptome, and proteome profiles. Comprehensive integrative analyses are performed to identify, validate and characterise definitive molecular subgroups. Corticotroph PitNETs separate into four robust and clinicopathologically distinct molecular subgroups, which are broadly distinguishable by microscopy using SSTR1, GATA3 and SSTR5 immunohistochemistry. An integrated stratification model incorporating these molecular subgroups demonstrates significant prognostic utility. Our findings support the establishment of a refined molecular-based corticotroph PitNET classification, the full clinical value of which will require validation in prospective studies. To facilitate future research, we provide an easy-to-use epigenomic classifier for corticotroph PitNETs.
- Open Access
- 16 June 2026
- Published by Springer Nature in Pituitary
- Vol. 29 (4) , 101
Three-week actigraphy to assess sleep behaviour and circadian rest-activity patterns in suspected and confirmed Cushing’s syndrome: an exploratory prospective cohort study
Purpose: Sleep disturbances are common in endogenous Cushing’s syndrome (CS), impair quality of life, and often persist despite remission. We evaluated the diagnostic value of actigraphy in suspected CS, characterised sleep and rest-activity patterns during remission, and examined associations between late-night salivary cortisol (LNSC) and objective sleep measures. Methods: Exploratory prospective single-centre cohort study at LMU Hospital Munich with two cohorts: (1) individuals evaluated for suspected CS and (2) patients in remission, stratified by recovered versus persistent adrenal insufficiency. Participants wore an ActTrust2 actigraph for 21 days, provided daily LNSC samples, and completed the Munich Chronotype Questionnaire. Results: Cohort 1 included 16 patients with confirmed CS and 13 with exclusion of CS. Actigraphy detected comparable sleep efficiency, fragmentation and circadian rest-activity rhythms in both groups, without distinct alterations attributable to active CS, except for a significantly earlier chronotype (p=0.022). Cohort 2 comprised 23 patients in remission (13 with persistent, 10 with recovered adrenal insufficiency) and showed similar sleep characteristics across subgroups. LNSC revealed high inter- and intraindividual variability without consistent associations with actigraphy-derived sleep parameters. Statistically significant effects were confined to patients with persistent adrenal insufficiency, in whom higher LNSC (likely reflecting non-physiological replacement therapy) was associated with earlier bedtime, longer time in bed, prolonged sleep-onset latency, and reduced sleep efficiency. Conclusion: Apart from chronotype, actigraphy showed limited discriminatory value between clinical groups. LNSC was highly variable and showed no consistent associations with sleep parameters, underscoring the need for improved biomarkers and monitoring strategies in CS.
- 16 June 2026
- Published by Springer Nature in Pituitary
- Vol. 29 (4) , 101
Open AccessThree-week actigraphy to assess sleep behaviour and circadian rest-activity patterns in suspected and confirmed Cushing’s syndrome: an exploratory prospective cohort study
Purpose: Sleep disturbances are common in endogenous Cushing’s syndrome (CS), impair quality of life, and often persist despite remission. We evaluated the diagnostic value of actigraphy in suspected CS, characterised sleep and rest-activity patterns during remission, and examined associations between late-night salivary cortisol (LNSC) and objective sleep measures. Methods: Exploratory prospective single-centre cohort study at LMU Hospital Munich with two cohorts: (1) individuals evaluated for suspected CS and (2) patients in remission, stratified by recovered versus persistent adrenal insufficiency. Participants wore an ActTrust2 actigraph for 21 days, provided daily LNSC samples, and completed the Munich Chronotype Questionnaire. Results: Cohort 1 included 16 patients with confirmed CS and 13 with exclusion of CS. Actigraphy detected comparable sleep efficiency, fragmentation and circadian rest-activity rhythms in both groups, without distinct alterations attributable to active CS, except for a significantly earlier chronotype (p=0.022). Cohort 2 comprised 23 patients in remission (13 with persistent, 10 with recovered adrenal insufficiency) and showed similar sleep characteristics across subgroups. LNSC revealed high inter- and intraindividual variability without consistent associations with actigraphy-derived sleep parameters. Statistically significant effects were confined to patients with persistent adrenal insufficiency, in whom higher LNSC (likely reflecting non-physiological replacement therapy) was associated with earlier bedtime, longer time in bed, prolonged sleep-onset latency, and reduced sleep efficiency. Conclusion: Apart from chronotype, actigraphy showed limited discriminatory value between clinical groups. LNSC was highly variable and showed no consistent associations with sleep parameters, underscoring the need for improved biomarkers and monitoring strategies in CS.
- Open Access
- 22 April 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (5)
Phaeochromocytomas and paragangliomas harbour tumour-initiating SOX2+ stem cells
Phaeochromocytomas (PCCs) and paragangliomas (PGLs) are rare neuroendocrine tumours that arise in the neural crest (NC)-derived adrenal medulla and the paraganglia, respectively. Approximately 10–15% of patients with PCCs and 35–40% with PGLs go on to develop metastatic disease, leading to a reported median overall survival of 7 years. The development of prognostic markers and subsequent personal therapeutic strategies are hindered by a lack of understanding of tumourigenesis. In other organs, cells with stem-like properties are at the root of tumour initiation and maintenance, due to their ability to self-renew and give rise to differentiated cells. We have recently shown that, in the human adrenal, a subset of sustentacular cells, endowed with a support role, are in fact SOX2+ postnatal adrenomedullary stem cells that are specified along the NC migratory route. In this study, we intended to determine if SOX2+ cells in PCCs and PGLs can behave as tumour-initiating stem cells. Using expression and transcriptomic studies, we demonstrate the presence of SOX2/SOX2-expressing cells across a broad range of PCCs and PGLs, irrespective of tumour aggressiveness, location, and causative mutation. In silico analyses reveal the co-expression of SOX2 and chromaffin cell markers in the tumour and reveal the active proliferation of these double-positive cells. Isolation of these cells in vitro in stem cell-promoting media, and their xenotransplantation on chicken chorioallantoic membranes, demonstrates that they have the potential to expand and metastasise in ovo, supporting their potential as tumour-initiating cells.
- 22 April 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (5)
Open AccessPhaeochromocytomas and paragangliomas harbour tumour-initiating SOX2+ stem cells
Phaeochromocytomas (PCCs) and paragangliomas (PGLs) are rare neuroendocrine tumours that arise in the neural crest (NC)-derived adrenal medulla and the paraganglia, respectively. Approximately 10–15% of patients with PCCs and 35–40% with PGLs go on to develop metastatic disease, leading to a reported median overall survival of 7 years. The development of prognostic markers and subsequent personal therapeutic strategies are hindered by a lack of understanding of tumourigenesis. In other organs, cells with stem-like properties are at the root of tumour initiation and maintenance, due to their ability to self-renew and give rise to differentiated cells. We have recently shown that, in the human adrenal, a subset of sustentacular cells, endowed with a support role, are in fact SOX2+ postnatal adrenomedullary stem cells that are specified along the NC migratory route. In this study, we intended to determine if SOX2+ cells in PCCs and PGLs can behave as tumour-initiating stem cells. Using expression and transcriptomic studies, we demonstrate the presence of SOX2/SOX2-expressing cells across a broad range of PCCs and PGLs, irrespective of tumour aggressiveness, location, and causative mutation. In silico analyses reveal the co-expression of SOX2 and chromaffin cell markers in the tumour and reveal the active proliferation of these double-positive cells. Isolation of these cells in vitro in stem cell-promoting media, and their xenotransplantation on chicken chorioallantoic membranes, demonstrates that they have the potential to expand and metastasise in ovo, supporting their potential as tumour-initiating cells.
- Open Access
- 2 March 2026
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 14 (4) , 327-336
Risk of recurrence after successful surgery for Cushing's disease and association with USP8 genotype and tumour size: an international, retrospective, longitudinal cohort study
- 2 March 2026
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 14 (4) , 327-336
Open AccessRisk of recurrence after successful surgery for Cushing's disease and association with USP8 genotype and tumour size: an international, retrospective, longitudinal cohort study
- Open Access
- 17 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (Supplement) , ii84-ii96
EndoCompass project: research roadmap for pituitary and neuroendocrine tumor endocrinology
Background: Endocrine science remains underrepresented in European Union research programs despite the fundamental role of hormone health in human wellbeing. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding toward endocrinology. The EndoCompass project—a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology, aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges. Methods: Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation in pituitary and neuroendocrine tumor endocrinology was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups. Results: Research priorities encompass congenital and acquired disorders, tumor development and progression, and neuroendocrine neoplasms. Key areas include genetic/epigenetic factors, tumor microenvironment, personalized treatment approaches, developing preclinical models, and implementing artificial intelligence. Special emphasis is placed on aggressive tumors, hypothalamic syndromes, and establishing pan-European biobanks and databases. Conclusions: This component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into pituitary-neuroendocrine disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact in endocrine health
- 17 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (Supplement) , ii84-ii96
Open AccessEndoCompass project: research roadmap for pituitary and neuroendocrine tumor endocrinology
Background: Endocrine science remains underrepresented in European Union research programs despite the fundamental role of hormone health in human wellbeing. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding toward endocrinology. The EndoCompass project—a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology, aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges. Methods: Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation in pituitary and neuroendocrine tumor endocrinology was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups. Results: Research priorities encompass congenital and acquired disorders, tumor development and progression, and neuroendocrine neoplasms. Key areas include genetic/epigenetic factors, tumor microenvironment, personalized treatment approaches, developing preclinical models, and implementing artificial intelligence. Special emphasis is placed on aggressive tumors, hypothalamic syndromes, and establishing pan-European biobanks and databases. Conclusions: This component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into pituitary-neuroendocrine disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact in endocrine health
- 28 July 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , e1461-e1462
Predicting Long-Term Outcomes in Cushing Disease: So Close and Yet So Far
- 28 July 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , e1461-e1462
Predicting Long-Term Outcomes in Cushing Disease: So Close and Yet So Far
- Open Access
Phaeochromocytomas and paragangliomas harbour tumour-initiating SOX2+ stem cells
Phaeochromocytomas (PCCs) and paragangliomas (PGLs), are rare neuroendocrine tumours that arise in the neural crest (NC)-derived adrenal medulla and the paraganglia, respectively. Approximately 10%-15% of patients with PCCs and 35%-40% with PGLs go on to develop metastatic disease, leading to a reported median overall survival of 7 years. The development of prognostic markers and subsequent personal therapeutic strategies are hindered by a lack of understanding of tumourigenesis. In other organs, cells with stem-like properties are at the root of tumour initiation and maintenance, due to their ability to self- renew and give rise to differentiated cells. We have recently shown that, in the human adrenal, a subset of sustentacular cells, endowed with a support role, are in fact SOX2+ postnatal adrenomedullary stem cells, that are specified along the neural crest migratory route. In this study, we intended to determine if SOX2+ cells in PCCs and PGLs can behave as tumour-initiating stem cells. Using expression and transcriptomic studies, we demonstrate the presence of SOX2/ SOX2 -expressing cells across a broad range of PCCs and PGLs, irrespective of tumour aggressiveness, location, and causative mutation. In silico analyses reveal the co-expression of SOX2 and chromaffin cell markers in the tumour, and the active proliferation of these double-positive cells. Isolation of these cells in vitro in stem cell-promoting media, and their xenotransplantation on chicken chorioallantoic membranes, demonstrates that they have the potential to expand and metastasise in ovo , supporting their potential as tumour-initiating cells.
Open AccessPhaeochromocytomas and paragangliomas harbour tumour-initiating SOX2+ stem cells
Phaeochromocytomas (PCCs) and paragangliomas (PGLs), are rare neuroendocrine tumours that arise in the neural crest (NC)-derived adrenal medulla and the paraganglia, respectively. Approximately 10%-15% of patients with PCCs and 35%-40% with PGLs go on to develop metastatic disease, leading to a reported median overall survival of 7 years. The development of prognostic markers and subsequent personal therapeutic strategies are hindered by a lack of understanding of tumourigenesis. In other organs, cells with stem-like properties are at the root of tumour initiation and maintenance, due to their ability to self- renew and give rise to differentiated cells. We have recently shown that, in the human adrenal, a subset of sustentacular cells, endowed with a support role, are in fact SOX2+ postnatal adrenomedullary stem cells, that are specified along the neural crest migratory route. In this study, we intended to determine if SOX2+ cells in PCCs and PGLs can behave as tumour-initiating stem cells. Using expression and transcriptomic studies, we demonstrate the presence of SOX2/ SOX2 -expressing cells across a broad range of PCCs and PGLs, irrespective of tumour aggressiveness, location, and causative mutation. In silico analyses reveal the co-expression of SOX2 and chromaffin cell markers in the tumour, and the active proliferation of these double-positive cells. Isolation of these cells in vitro in stem cell-promoting media, and their xenotransplantation on chicken chorioallantoic membranes, demonstrates that they have the potential to expand and metastasise in ovo , supporting their potential as tumour-initiating cells.
- Top Cited PapersOpen Access
- 30 May 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (6) , G1-G34
Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas
Pituitary tumours, originating from endocrine cells of the anterior pituitary, are quite common, and in most cases well-controlled by surgery or medical treatment. However, a small subset of pituitary tumours presents with multiple local recurrences or tumour progression despite combined surgical, medical or radiotherapeutic treatment. These are known as aggressive pituitary tumours (APT); also called aggressive pituitary neuroendocrine tumours (PitNETs); or, in the rare case of metastases, pituitary carcinomas (PC) or metastatic PitNETs. Early identification of APT is challenging but is of major clinical importance as they are associated with an increased morbidity and mortality even in the absence of metastases. Here, we provide a revision of the first international, interdisciplinary European Society of Endocrinology (ESE) clinical practice guideline on APTs and PC (2018). Since publication of the 2018 guideline, results from the second ESE survey on APT and PC were published, and more data on APT treatment, including temozolomide, immune checkpoint inhibitors and bevacizumab, emerged. These data are reviewed in this guideline and translated into a practical algorithm to guide APT and PC management. Furthermore, standardized reporting of imaging and histopathological investigations of these tumours is proposed, and the role of molecular analysis is discussed. Last, a section is dedicated to special circumstances such as APT in pregnancy.
- 30 May 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (6) , G1-G34
Top Cited PapersOpen AccessRevised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas
Pituitary tumours, originating from endocrine cells of the anterior pituitary, are quite common, and in most cases well-controlled by surgery or medical treatment. However, a small subset of pituitary tumours presents with multiple local recurrences or tumour progression despite combined surgical, medical or radiotherapeutic treatment. These are known as aggressive pituitary tumours (APT); also called aggressive pituitary neuroendocrine tumours (PitNETs); or, in the rare case of metastases, pituitary carcinomas (PC) or metastatic PitNETs. Early identification of APT is challenging but is of major clinical importance as they are associated with an increased morbidity and mortality even in the absence of metastases. Here, we provide a revision of the first international, interdisciplinary European Society of Endocrinology (ESE) clinical practice guideline on APTs and PC (2018). Since publication of the 2018 guideline, results from the second ESE survey on APT and PC were published, and more data on APT treatment, including temozolomide, immune checkpoint inhibitors and bevacizumab, emerged. These data are reviewed in this guideline and translated into a practical algorithm to guide APT and PC management. Furthermore, standardized reporting of imaging and histopathological investigations of these tumours is proposed, and the role of molecular analysis is discussed. Last, a section is dedicated to special circumstances such as APT in pregnancy.
- Open Access
- 20 May 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (6) , S41-S52
Prevalence and clinical associations of USP8 variants in corticotroph tumours: a systematic review and aggregate data meta-analysis of 2171 cases
Objective: Somatic USP8 variants are common in corticotroph tumours, but their reported prevalence and association with clinical characteristics vary widely among publications. Aim: To determine the prevalence and clinical relevance of USP8 variants based on published evidence. Design and methods: We conducted a systematic review and meta-analysis of existing literature. We used PubMed, Embase, and Web of Science databases. The inclusion criteria were original studies including ≥5 patients with Cushing's disease reporting genetic USP8 status. The exclusion criteria were no human research, unclear USP8 information, and case reports (<5 patients). A random-effects model meta-analysis and meta-regression were conducted. Studies reporting functional corticotroph tumours and also silent/non-functioning tumours were not excluded. Results: From 6782 extracted records, 44 studies summarizing 51 records were included in our meta-analysis (total n = 2171 cases, 692 with USP8 variants). Pooled prevalence was 31.1% (95% CI, 26.5%-36.0%) and was higher in cases with functional tumours (34.1%; 95% CI, 29.4%–39.1%). Patients with USP8 variants were mostly female (odds ratios [OR] 4.52, 95% CI, 3.39-6.02) and in average 4.47 years younger at diagnosis (95% CI, 2.28-6.65 years younger). USP8 status was associated with higher odds for postoperative remission (OR 1.76, 95% CI, 1.18-2.63) and recurrence (OR 2.38, 95% CI, 1.03-5.48). There was no clear evidence of association with any other clinical or tumour variable included in our analysis, mostly due to heterogeneity among studies. Meta-regression analysis showed that the variability in the prevalence of USP8 variants among studies was related to female/male ratio (adjusted R2 = 0.301), but not to other variables, such as tumour size or invasion. Conclusions: The present meta-analysis shows that patients with USP8 variant tumours are mostly female, diagnosed at younger age, more likely to achieve postoperative remission, but at a higher risk of recurrence than those with tumours carrying the reference allele.
- 20 May 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (6) , S41-S52
Open AccessPrevalence and clinical associations of USP8 variants in corticotroph tumours: a systematic review and aggregate data meta-analysis of 2171 cases
Objective: Somatic USP8 variants are common in corticotroph tumours, but their reported prevalence and association with clinical characteristics vary widely among publications. Aim: To determine the prevalence and clinical relevance of USP8 variants based on published evidence. Design and methods: We conducted a systematic review and meta-analysis of existing literature. We used PubMed, Embase, and Web of Science databases. The inclusion criteria were original studies including ≥5 patients with Cushing's disease reporting genetic USP8 status. The exclusion criteria were no human research, unclear USP8 information, and case reports (<5 patients). A random-effects model meta-analysis and meta-regression were conducted. Studies reporting functional corticotroph tumours and also silent/non-functioning tumours were not excluded. Results: From 6782 extracted records, 44 studies summarizing 51 records were included in our meta-analysis (total n = 2171 cases, 692 with USP8 variants). Pooled prevalence was 31.1% (95% CI, 26.5%-36.0%) and was higher in cases with functional tumours (34.1%; 95% CI, 29.4%–39.1%). Patients with USP8 variants were mostly female (odds ratios [OR] 4.52, 95% CI, 3.39-6.02) and in average 4.47 years younger at diagnosis (95% CI, 2.28-6.65 years younger). USP8 status was associated with higher odds for postoperative remission (OR 1.76, 95% CI, 1.18-2.63) and recurrence (OR 2.38, 95% CI, 1.03-5.48). There was no clear evidence of association with any other clinical or tumour variable included in our analysis, mostly due to heterogeneity among studies. Meta-regression analysis showed that the variability in the prevalence of USP8 variants among studies was related to female/male ratio (adjusted R2 = 0.301), but not to other variables, such as tumour size or invasion. Conclusions: The present meta-analysis shows that patients with USP8 variant tumours are mostly female, diagnosed at younger age, more likely to achieve postoperative remission, but at a higher risk of recurrence than those with tumours carrying the reference allele.